Global Neuroendocrine Tumors Report 2013
Research and Markets has announced the addition of the "Global Neuroendocrine Tumors Report 2013" report to their offering. 'Neuroendocrine Tumors - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Neuroendocrine Tumors, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuroendocrine Tumors. This analysis is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Neuroendocrine Tumors. - A review of the Neuroendocrine Tumors products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Neuroendocrine Tumors pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Neuroendocrine Tumors. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Neuroendocrine Tumors pipeline depth and focus of Indication therapeutics. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Neuroendocrine Tumors Overview Therapeutics Development An Overview of Pipeline Products for Neuroendocrine Tumors Companies Involved in Neuroendocrine Tumors Therapeutics Development Drug Profiles - MK-2206 - panobinostat - DG-3173 - everolimus - everolimus - edotreotide Labeled Yttrium 90 - edotreotide Labeled Yttrium 90 - TH-302 - lanreotide acetate - melphalan - IT-139 - vantictumab - 177Lu-DOTA-TATE - pasireotide LAR - Peptides For Cancer Featured News & Press Releases Appendix Companies Mentioned - Delcath Systems - Gradalis - Ipsen - Merck & Co - Nobelpharma - Novartis - OncoMed Pharmaceuticals - Progenics Pharmaceuticals - Tekmira Pharmaceuticals - Threshold Pharmaceuticals For more information CONTACT: Research and Markets, Laura Wood, Senior Manager Fax from USA: 646-607-1907
